4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (NASDAQ:FDMT) announced positive interim 24-week data from its Phase 2 PRISM trial for wet AMD, presented at the ASRS Annual Scientific Meeting.
July 17, 2024 | 9:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics (NASDAQ:FDMT) announced positive interim 24-week data from its Phase 2 PRISM trial for wet AMD, presented at the ASRS Annual Scientific Meeting.
The positive interim data from the Phase 2 PRISM trial for wet AMD is likely to boost investor confidence in FDMT's pipeline and its potential market impact. The presentation at a major scientific meeting further validates the significance of the results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100